Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).

British journal of cancer·2026
Same author

Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.

NPJ breast cancer·2025
Same author

Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial.

The British journal of surgery·2025
Same author

A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Breast (Edinburgh, Scotland)·2025
Same author

Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial.

International journal of radiation oncology, biology, physics·2025

関連する実験動画

Updated: Jun 21, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

胃がん 胃がん 胃がん

Henk H Hartgrink1, Edwin P M Jansen, Nicole C T van Grieken

  • 1Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.

Lancet (London, England)
|July 24, 2009
PubMed
まとめ

胃がんの予防とパーソナライズされた治療は,死亡率を下げるための鍵です. 戦略は,ヘリコバクター・パイロリや遺伝子変異などの危険因子を含み,最新の外科療法や化学療法アプローチを伴うものです.

科学分野:

  • 腫瘍学 腫瘍学
  • 胃腸内科 胃腸内科
  • 公衆衛生は公衆衛生である.

背景:

  • 胃がんは,世界中でがんによる死亡の主な原因であり,地理的な発生率の有意な変動があります.
  • 手術を含む現在の治療方法は,進行した段階で生存率と局所的制御を改善する上で限界があります.
  • パーソナライズされた治療と予防戦略は,胃がんによる死亡率を下げるために極めて重要です.

研究 の 目的:

  • 胃がんの発生率,原因,および病理学の最新の概要を提供します.
  • 外科技術やネオアジュヴァント/アドジュヴァント療法を含む,胃がんの現在のおよび新しい治療戦略をレビューする.
  • 患者のアウトカムに対するケースロードの影響と,治療における遺伝子シグネチャーの可能性を探求する.

主な方法:

  • 胃がんの流行病学,危険因子,治療結果に関する現在の文献のレビュー.
  • 最小侵襲手術,化学療法,放射線療法,標的型遺伝子療法などの既定および新興の治療方法の分析.
  • 専門がんセンターの役割を含む,患者の治療結果に影響を与える要因の検討.

主要な成果:

  • 胃がんの発生率は地域によって異なるため,ヘリコバクター・パイロリ,宿主遺伝,前駆体病変,環境要因に基づいた,個別の予防戦略が必要である.

さらに関連する動画

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

関連する実験動画

Last Updated: Jun 21, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

  • 手術は基礎でありながら,進行した疾患に対する有効性は限られている. 最小侵襲的技術は初期段階に適している.
  • ネオアジュヴァント/アジュヴァント療法,遺伝子シグネチャー,および症例数の影響を含む新しい戦略は,患者の治療結果を改善する見込みを示しています.

    • 結論:

    • 効果的な胃がん管理には,パーソナライズされた予防と先進的な治療戦略を組み合わせた多面的なアプローチが必要です.
    • 遺伝子シグネチャーと治療量の影響に関するさらなる研究は,患者の生存率と生活の質を最適化するために不可欠です.
    • 新しい治療方法の統合とリスクプロファイルの理解は,胃がんの世界的な負担を軽減するために重要です.